Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18955504 | DESMOPRESSIN ORAL COMPOSITIONS | November 2024 | May 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18674657 | POLYPEPTIDES HAVING ANTI-SENESCENT EFFECTS AND USES THEREOF | May 2024 | January 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18625923 | DESMOPRESSIN ORAL COMPOSITIONS | April 2024 | October 2024 | Allow | 38 | 1 | 1 | Yes | No |
| 18604400 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | March 2024 | November 2024 | Allow | 8 | 1 | 1 | No | No |
| 18386839 | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | November 2023 | June 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18484819 | LIQUID DALBAVANCIN COMPOSITIONS | October 2023 | May 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18365367 | LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOF | August 2023 | March 2024 | Allow | 7 | 1 | 0 | No | No |
| 18214651 | COMPOSITIONS AND METHODS OF CELL ATTACHMENT | June 2023 | April 2025 | Abandon | 22 | 1 | 1 | Yes | No |
| 18307124 | SOMATOSTATIN RECEPTOR AGONIST FORMULATIONS | April 2023 | March 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18139030 | COMPOUNDS | April 2023 | June 2025 | Abandon | 26 | 2 | 1 | No | No |
| 18130299 | TREATMENT OF HMGB1-MEDIATED INFLAMMATION | April 2023 | September 2024 | Abandon | 17 | 1 | 1 | No | No |
| 18170994 | COMPOSITIONS AND METHOD FOR OPTIMIZED PEPTIDE VACCINES USING RESIDUE OPTIMIZATION | February 2023 | April 2024 | Allow | 14 | 2 | 1 | Yes | No |
| 18078518 | PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES | December 2022 | June 2025 | Abandon | 31 | 1 | 1 | Yes | No |
| 17823018 | BCL-W Polypeptides and Mimetics for Treating or Preventing Chemotherapy-Induced Peripheral Neuropathy and Hearing Loss | August 2022 | June 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 17810565 | GLYCOTARGETING THERAPEUTICS | July 2022 | May 2025 | Abandon | 35 | 2 | 1 | No | No |
| 17810573 | GLYCOTARGETING THERAPEUTICS | July 2022 | June 2025 | Abandon | 35 | 2 | 1 | No | No |
| 17810574 | GLYCOTARGETING THERAPEUTICS | July 2022 | June 2025 | Abandon | 35 | 2 | 1 | No | No |
| 17810561 | GLYCOTARGETING THERAPEUTICS | July 2022 | May 2025 | Abandon | 35 | 2 | 1 | No | No |
| 17845144 | COMPOSITIONS AND METHODS FOR TARGETING NUCLEAR IMPORT SHUTTLES AND TREATING INFLAMMATORY DISORDERS | June 2022 | April 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 17826659 | LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOF | May 2022 | March 2025 | Allow | 33 | 2 | 1 | Yes | No |
| 17729290 | COMPOSITIONS AND METHOD FOR OPTIMIZED PEPTIDE VACCINES USING RESIDUE OPTIMIZATION | April 2022 | January 2023 | Allow | 8 | 2 | 1 | Yes | No |
| 17718906 | RECOMBINANT GLYCOSYLATED ECULIZUMAB AND ECULIZUMAB VARIANTS | April 2022 | November 2024 | Abandon | 32 | 1 | 1 | No | No |
| 17650975 | RECOMBINANT VECTOR FOR EXPRESSING TARGET PROTEIN IN PLANT CELL | February 2022 | October 2023 | Allow | 20 | 0 | 1 | Yes | No |
| 17589588 | ANTIBIOTIC CANNABINOID-TERPENE FORMULATIONS | January 2022 | June 2023 | Allow | 17 | 2 | 1 | Yes | No |
| 17566249 | PEPTIDE AND METHOD FOR MANUFACTURING SAME | December 2021 | January 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17550098 | Cystatin C and Cystatin 9 to Treat Inflammation Caused by Bacteria | December 2021 | May 2025 | Abandon | 41 | 2 | 1 | Yes | No |
| 17527408 | WHEY PROTEIN MICELLES AGAINST MUSCLE ATROPHY AND SARCOPENIA | November 2021 | March 2025 | Abandon | 40 | 3 | 0 | Yes | No |
| 17607247 | ANTIBIOTIC CANNABINOID-TERPENE FORMULATIONS | October 2021 | October 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17604925 | SHORT SYNTHETIC PEPTIDES AND THEIR USES FOR TREATING RETINAL DEGENERATIVE DISEASES AND/OR TISSUE INJURIES | October 2021 | September 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17501486 | ALPHA-V BETA-6 INTEGRIN LIGANDS AND USES THEREOF | October 2021 | May 2024 | Abandon | 31 | 1 | 1 | Yes | No |
| 17401929 | PHARMACEUTICAL COMPOSITIONS | August 2021 | March 2025 | Allow | 43 | 2 | 1 | No | No |
| 17396947 | ARTIFICIAL SYNAPSES | August 2021 | November 2024 | Abandon | 40 | 5 | 1 | Yes | No |
| 17383617 | PLANT MESSENGER PACKS ENCAPSULATING POLYPEPTIDES AND USES THEREOF | July 2021 | February 2024 | Abandon | 31 | 4 | 0 | Yes | No |
| 17366332 | PHARMACEUTICAL COMPOSITION COMPRISING A GLP-1 AGONIST, AN INSULIN AND METHIONINE | July 2021 | July 2024 | Abandon | 36 | 2 | 0 | No | No |
| 17352506 | INJECTABLE COMPOSITION FOR PREVENTING HAIR LOSS OR STIMULATING HAIR GROWTH | June 2021 | July 2024 | Allow | 37 | 2 | 1 | Yes | No |
| 17350363 | CONTROLLED RELEASE PEPTIDE FORMULATIONS | June 2021 | October 2024 | Abandon | 40 | 2 | 1 | No | No |
| 17348023 | METHOD AND FORMULATION FOR INHALATION | June 2021 | August 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17298512 | Modified GIP Peptide Analogues | May 2021 | March 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17306435 | ENGINEERED PD-1 VARIANTS | May 2021 | October 2023 | Allow | 29 | 1 | 1 | Yes | No |
| 17243096 | COMPOSITIONS AND METHOD FOR OPTIMIZED PEPTIDE VACCINES USING RESIDUE OPTIMIZATION | April 2021 | December 2021 | Allow | 8 | 3 | 1 | Yes | No |
| 17202064 | IDENTIFICATION OF CHANNELRHODOPSIN-2 (CHR2) MUTATIONS AND METHODS OF USE | March 2021 | May 2024 | Abandon | 38 | 2 | 1 | No | No |
| 17197980 | MULTIFUNCTIONAL OPIOID RECEPTOR LIGANDS AND METHODS OF TREATING PAIN | March 2021 | April 2025 | Abandon | 49 | 2 | 1 | No | No |
| 17165070 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING POLYCYSTIC OVARY SYNDROME | February 2021 | January 2023 | Abandon | 23 | 1 | 1 | No | No |
| 17264793 | ENGINEERED HEMICHANNELS, ENGINEERED VESICLES, AND USES THEREOF | January 2021 | February 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17141778 | PEPTIDES FOR USE IN PROMOTING TRANSPORT OF GLUCOSE | January 2021 | April 2025 | Allow | 52 | 2 | 1 | Yes | Yes |
| 17138448 | PEPTIDIC TGF-BETA ANTAGONISTS | December 2020 | June 2023 | Allow | 29 | 1 | 1 | Yes | No |
| 17253333 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | December 2020 | May 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17113957 | METHODS FOR DIAGNOSING AND ASSESSING RISK OF DEVELOPING GLOMERULOSCLEROSIS | December 2020 | June 2024 | Allow | 42 | 2 | 1 | Yes | No |
| 15734957 | METHODS OF USE OF CD24 FOR THE PREVENTION AND TREATMENT OF LEUKEMIA RELAPSE | December 2020 | October 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 17086786 | Q-PEPTIDE HYDROGEL PROMOTES IMMUNE MODULATION AND MACROPHAGE DIFFERENTIATION | November 2020 | May 2023 | Allow | 31 | 1 | 1 | Yes | No |
| 17075295 | LONG-ACTING FATTY ACID-CONJUGATED GnRH DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | October 2020 | March 2022 | Abandon | 17 | 2 | 1 | Yes | No |
| 17032540 | PREPARATION AND APPLICATION OF SURFACE DOUBLE MODIFIED HUMAN SERUM ALBUMIN AS TARGETING NANO DRUG CARRIER | September 2020 | June 2024 | Abandon | 45 | 2 | 1 | No | No |
| 17041459 | Targeted Thrombolysis for Treatment of Microvascular Thrombosis | September 2020 | September 2024 | Abandon | 48 | 1 | 1 | Yes | No |
| 17041638 | ANTIMICROBIAL, BACTERIOPHAGE-DERIVED POLYPEPTIDES AND THEIR USE AGAINST GRAM-NEGATIVE BACTERIA | September 2020 | July 2024 | Abandon | 46 | 1 | 1 | No | No |
| 17016473 | TREATMENT OF HMGB1-MEDIATED INFLAMMATION | September 2020 | December 2022 | Allow | 27 | 1 | 1 | Yes | No |
| 16997760 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | August 2020 | September 2022 | Abandon | 25 | 0 | 1 | No | No |
| 16987764 | MODULATION OF STRUCTURED POLYPEPTIDE SPECIFICITY | August 2020 | April 2023 | Allow | 32 | 2 | 1 | Yes | No |
| 16943822 | MULTIPARTICULATE GRANULATE COMPRISING INSULIN | July 2020 | December 2022 | Abandon | 28 | 1 | 0 | No | No |
| 16943114 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | July 2020 | February 2025 | Allow | 55 | 4 | 1 | Yes | No |
| 16965814 | AFFINITY LIGANDS FOR ANTIBODY FC REGION | July 2020 | October 2024 | Allow | 50 | 4 | 1 | No | No |
| 16937316 | COMPOUNDS USEFUL TO TREAT METABOLIC DISORDERS | July 2020 | April 2025 | Abandon | 57 | 4 | 1 | No | No |
| 16936177 | POLYPEPTIDES HAVING ANTI-SENESCENT EFFECTS AND USES THEREOF | July 2020 | January 2025 | Allow | 54 | 6 | 1 | Yes | No |
| 16911712 | GALACTOENGINEERED IMMUNOGLOBULIN 1 ANTIBODIES | June 2020 | August 2022 | Abandon | 26 | 0 | 1 | No | No |
| 16910945 | PROPYLENE GLYCOL-CONTAINING PEPTIDE FORMULATIONS WHICH ARE OPTIMAL FOR PRODUCTION AND FOR USE IN INJECTION DEVICES | June 2020 | December 2022 | Abandon | 30 | 3 | 1 | Yes | Yes |
| 16955896 | POLYMYXIN-BASED PHARMACEUTICAL COMPOSITION FOR TREATING INFECTIOUS DISEASES | June 2020 | August 2021 | Allow | 14 | 2 | 1 | No | No |
| 16903107 | CYSTATIN C AND CYSTATIN 9 TO TREAT GUT INFLAMMATION CAUSED BY THERMAL INJURY | June 2020 | April 2024 | Allow | 46 | 3 | 1 | Yes | No |
| 16899192 | MODULATION OF STRUCTURED POLYPEPTIDE SPECIFICITY | June 2020 | October 2023 | Allow | 40 | 3 | 1 | Yes | No |
| 16768584 | PEPTIDE HORMONE WITH ONE OR MORE O-GLYCANS | May 2020 | May 2023 | Abandon | 35 | 1 | 1 | Yes | No |
| 16881314 | USE OF THYMOSIN ALPHA FOR THE TREATMENT OF SEPSIS | May 2020 | November 2022 | Abandon | 30 | 1 | 1 | Yes | No |
| 16876683 | NOVEL MODULATORS OF MELANOCORTIN RECEPTORS FOR THE TREATMENT OF DEPRESSION AND ANXIETY | May 2020 | September 2022 | Allow | 28 | 2 | 1 | Yes | No |
| 16763963 | USE OF CELL MEMBRANE-BOUND SIGNALING FACTORS | May 2020 | November 2024 | Abandon | 54 | 3 | 1 | No | No |
| 15733085 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF WOUNDS | May 2020 | March 2023 | Allow | 34 | 1 | 2 | Yes | No |
| 16872156 | METHODS, COMPOSITIONS, AND KITS FOR DETECTION OF ASPERGILLOSIS | May 2020 | March 2023 | Allow | 34 | 2 | 1 | Yes | No |
| 16870648 | SUBSTITUTED UREA DEPSIPEPTIDE ANALOGS AS ACTIVATORS OF THE CLPP ENDOPEPTIDASE | May 2020 | April 2024 | Abandon | 47 | 2 | 1 | No | No |
| 16868850 | Factor VII Composition Having a Substantially Homogeneous Isoelectric Point | May 2020 | December 2022 | Abandon | 32 | 2 | 1 | No | No |
| 16868803 | Factor VII Composition Having a Substantially Homogenous Isoelectric Point | May 2020 | January 2022 | Allow | 20 | 1 | 1 | Yes | No |
| 16760658 | METHODS TO PREVENT TERATOGENICITY OF IMID LIKE MOLECULES AND IMID BASED DEGRADERS/PROTACS | April 2020 | April 2024 | Abandon | 48 | 2 | 1 | No | No |
| 16861496 | THE COMPBODY - A MULTIVALENT TARGET BINDER | April 2020 | November 2023 | Allow | 43 | 2 | 1 | Yes | No |
| 16858557 | METHODS AND COMPOSITIONS FOR MANAGEMENT OF GASTROINTESTINAL DISORDERS | April 2020 | January 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 16755636 | CANCER VACCINE COMPOSITIONS AND METHODS FOR USING SAME TO TREAT CANCER | April 2020 | April 2023 | Abandon | 36 | 0 | 1 | No | No |
| 16832465 | HISTONE ANTI-CANCER VACCINES | March 2020 | May 2023 | Allow | 37 | 2 | 1 | Yes | No |
| 16812687 | GLP-1 FUSION PROTEINS AND USES THEREOF | March 2020 | May 2022 | Abandon | 26 | 1 | 1 | No | No |
| 16641959 | FUSION PROTEINS COMPRISING DETECTABLE TAGS, NUCLEIC ACID MOLECULES, AND METHOD OF TRACKING A CELL | February 2020 | January 2024 | Abandon | 47 | 1 | 1 | No | No |
| 16799350 | COMPOSITIONS AND METHODS FOR TARGETING NUCLEAR IMPORT SHUTTLES AND TREATING INFLAMMATORY DISORDERS | February 2020 | February 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 16640754 | IMMUNOPROTEASOME INHIBITORS AND IMMUNOSUPPRESSIVE AGENT IN THE TREATMENT OF AUTOIMMUNE DISORDERS | February 2020 | December 2023 | Abandon | 46 | 3 | 1 | Yes | No |
| 16639445 | APOM-FC FUSION PROTEINS AND USES THEREOF | February 2020 | February 2025 | Allow | 60 | 5 | 1 | Yes | No |
| 16789196 | PHARMACEUTICAL COMPOSITIONS AND PREPARATIONS FOR ADMINISTRATION TO THE EYE | February 2020 | January 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 16752168 | METHODS FOR MITIGATING LIVER INJURY AND PROMOTING LIVER HYPERTROPHY, REGENERATION AND CELL ENGRAFTMENT IN CONJUNCTION WITH RADIATION AND/OR RADIOMIMETIC TREATMENTS | January 2020 | June 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16631849 | METHODS FOR PURIFYING PROTEINS HAVING A TUBULIN CARBOXYPEPTIDASE ACTIVITY AND PEPTIDIC BASED INHIBITORS THEREOF | January 2020 | May 2025 | Allow | 60 | 5 | 1 | Yes | No |
| 16745520 | CYCLIC PEPTIDE AND A MEDICAMENT, EXTERNAL PREPARATION AND COSMETIC COMPRISING SAID CYCLIC PEPTIDE | January 2020 | April 2024 | Allow | 51 | 3 | 1 | Yes | No |
| 16630384 | COMPOSITIONS AND METHODS FOR WOUND CLOSURE | January 2020 | November 2022 | Abandon | 34 | 0 | 1 | No | No |
| 16627383 | METHOD FOR DIRECT REPROGRAMMING OF URINE CELLS INTO KERATINOCYTE STEM CELLS AND METHOD FOR PREPARING COMPOSITION FOR PROMOTING SKIN REGENERATION USING REPROGRAMMED KERATINOCYTE STEM CELLS | December 2019 | January 2023 | Abandon | 37 | 0 | 1 | No | No |
| 16626458 | A UNIVERSAL VACCINE BASED ON SHARED TUMOR NEOANTIGENS FOR PREVENTION AND TREATMENT OF MICRO SATELLITE INSTABLE (MSI) CANCERS | December 2019 | September 2022 | Allow | 33 | 1 | 1 | Yes | No |
| 16723757 | GLYCOTARGETING THERAPEUTICS | December 2019 | March 2023 | Allow | 39 | 4 | 1 | Yes | No |
| 16724067 | GLYCOTARGETING THERAPEUTICS | December 2019 | August 2023 | Allow | 44 | 4 | 1 | Yes | No |
| 16723774 | GLYCOTARGETING THERAPEUTICS | December 2019 | March 2023 | Allow | 39 | 4 | 1 | Yes | No |
| 16723914 | GLYCOTARGETING THERAPEUTICS | December 2019 | August 2023 | Allow | 44 | 4 | 1 | Yes | No |
| 16723280 | METHOD FOR SYNTHESIS OF PROTEIN AMPHIPHILES | December 2019 | December 2023 | Allow | 47 | 2 | 1 | Yes | No |
| 16496725 | METHOD FOR PREPARING A LIQUID EXTRACT OF PHYCOBILIPROTEINS, IN PARTICULAR PHYCOCYANIN, FROM CYANOBACTERIA OR MICROALGAE AND EXTRACT THUS OBTAINED | December 2019 | March 2023 | Abandon | 42 | 1 | 1 | No | No |
| 16623225 | FIBRONECTIN BINDING DOMAIN CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF | December 2019 | January 2025 | Allow | 60 | 3 | 2 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner D' AMBROSIO, THEA.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner D' AMBROSIO, THEA works in Art Unit 1654 and has examined 312 patent applications in our dataset. With an allowance rate of 54.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner D' AMBROSIO, THEA's allowance rate of 54.8% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by D' AMBROSIO, THEA receive 2.61 office actions before reaching final disposition. This places the examiner in the 88% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by D' AMBROSIO, THEA is 35 months. This places the examiner in the 19% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +66.5% benefit to allowance rate for applications examined by D' AMBROSIO, THEA. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 19.8% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 25.3% of cases where such amendments are filed. This entry rate is in the 26% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 80.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 60% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 71.4% of appeals filed. This is in the 53% percentile among all examiners. Of these withdrawals, 90.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 81.8% are granted (fully or in part). This grant rate is in the 93% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.2% of allowed cases (in the 58% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.